LEADER IN NASAL DECOLONIZATION
™
LEADER IN NASAL DECOLONIZATION
™
Nozin.com 877-669-4648
Ask a Nozin advisor for a savings analysis
and professional samples.
• Safely Reduce MRSA Contact Precautions
• 30 Bed ICU Could Save $600,000 Per Year*
• Improve Patient Care and Satisfaction
1. Huang SS et al. Targeted versus universal. N Engl J Med, 2013: 368(24): 2255-65. Mupirocin and CHG used in study. 2. Huang SS et al. Cost Savings of Universal Decolonization
to Prevent Intensive Care Unit Infection. ICHE, 2014: 35 (S3): S23-S31. 3.
Steed L, et al. Reduction of nasal Staphylococcus aureus carriage. AJIC, 2014: 42(8): 841-846. ©2018 Global
Life Technologies Corp. All rights reserved. Made in USA. Nozin®, Nasal Sanitizer®, Leader in Nasal Decolonization™ are trademarks of Global Life Technologies Corp. Nozin® Nasal
Sanitizer® antiseptic is an OTC topical drug. No claim is made that it has an eect on any specic disease. *
Savings estimates are for example only. Any actual savings may vary.
Nasal Decolonization is
The Key to Reduce CP
Contact isolation precautions (CP) can adversely aect
patient care, utilization of sta and costs. Research shows
that universal skin and nasal decolonization can help.
1, 2
Nozin ICU programs use universal patient decolonization
to safely reduce screening and CP for MRSA colonization.
With the Nozin program, healthcare facilities are able to
lessen CP burdens on patients, address sta isolation
fatigue, reduce costs and support antibiotic stewardship.
Nozin® Nasal Sanitizer® antiseptic is clinically proven to
decolonize nasal S. aureus day one without antibiotics.
3
Learn how a Nozin program can be the key to safely
reducing CP in critical care at your facility.
See Nozin at APIC 2018 Booth #1307
